Product Description: Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression in patients with mild Alzheimer’s disease (AD)[1]. Azeliragon also can cross the blood-brain barrier (BBB)[2].
Applications: Neuroscience-Neurodegeneration
Formula: C32H38ClN3O2
References: [1]Burstein AH, et al. Assessment of Azeliragon QTc Liability Through Integrated, Model-Based Concentration QTc Analysis. Clin Pharmacol Drug Dev. 2019 May;8(4):426-435./[2]Bongarzone S, et al. Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective. J Med Chem. 2017 Sep 14;60(17):7213-7232./[3]Chen Y, et al. RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol. 2008 Sep 15;181(6):4272-8.
CAS Number: 603148-36-3
Molecular Weight: 532.12
Compound Purity: 99.37
Research Area: Neurological Disease; Cancer
Solubility: DMSO : 50 mg/mL (ultrasonic)
Target: Amyloid-β
English
Deutsch
